What genetic mutations are commonly found in Ovarian Cancer

Genetic Mutations in Ovarian Cancer

Looking at ovarian cancer from a genetic perspective, several mutations have been identified as important risk factors. Let me walk you through the most significant ones and what they mean for patients.

The Most Common Mutations: BRCA1 and BRCA2

BRCA1 and BRCA2 mutations are the most well-known genetic risk factors for ovarian cancer. According to the NCCN Guidelines for Ovarian Cancer, these mutations account for approximately 15% of all ovarian cancer cases (with a range of 7-21% depending on the population studied).

Here's what this means in practical terms:

• These genes normally act as "tumor suppressors" — they help prevent cells from becoming cancerous
• When mutated, they lose this protective function
• Women with BRCA1/2 mutations have significantly elevated lifetime risk for ovarian cancer
• The presence of a BRCA mutation in your tumor is also important because it can predict response to specific treatments, particularly PARP inhibitors (a class of targeted drugs)

Other Important Mutations Beyond BRCA1/2

The NCCN Guidelines identify several additional genes associated with ovarian cancer risk:

Homologous Recombination (HR) Repair Genes:

• RAD51C and RAD51D — involved in DNA repair
• PALB2 — works with BRCA2 in DNA repair
• BRIP1 — interacts with BRCA1
• NBN — involved in DNA damage response

Lynch Syndrome Genes:

• MLH1, MSH2, MSH6, PMS2 — these are mismatch repair genes associated with Lynch syndrome, which increases ovarian cancer risk

Other Genes:

• ATM — regulates DNA damage response
• STK11 — tumor suppressor gene

How Common Are These Non-BRCA Mutations?

According to the NCCN Guidelines, studies using large gene panels have found that 3-8% of ovarian cancer patients carry mutations in genes OTHER than BRCA1 and BRCA2 that are known to increase ovarian cancer susceptibility.

This is important because it means:

• Even if you don't have a BRCA mutation, you may still carry a mutation in another cancer-related gene
• Comprehensive genetic testing (not just BRCA testing) can identify these additional mutations
• Some of these mutations may also influence treatment options

Why This Matters for Your Care

According to NCCN Guidelines, upon pathologic confirmation of ovarian cancer, patients should be referred for:

• Germline testing (inherited mutations from your parents)
• Somatic testing (mutations that developed in the cancer cells themselves)

This testing is particularly important because:

1. Treatment Selection: BRCA1/2 mutations and other HR-deficiency status inform eligibility for PARP inhibitor maintenance therapy
2. Family Planning: If you carry a germline mutation, your relatives may benefit from genetic counseling and testing
3. Surveillance: Knowing your genetic status helps guide screening recommendations for other cancers
4. Clinical Trials: Many trials are designed specifically for patients with certain genetic mutations

Questions to Ask Your Healthcare Team

1. Have I been tested for BRCA1 and BRCA2 mutations? If not, why not, and when can this testing be done?
2. Should I have comprehensive multi-gene panel testing that looks beyond just BRCA1/2?
3. What do my specific genetic test results mean for my treatment options?
4. If I have a germline mutation, what screening or preventive measures should my family members consider?
5. How will my genetic status influence my maintenance therapy options after chemotherapy?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Guidelines for Ovarian Cancer (Version 3.2025)